

**REMARKS**


Claims 2 and 33 - 35 are presented in this application. Claims 1, 3 - 32, and 36 - 38 are cancelled. No new claims have been added.

The Examiner has indicated that claim 2 is allowed. Dependency of claims 33 - 35 has been amended to claim 2. In view of the amendments and cancellations of claims, the rejection of claims under 35 USC 1021(a), is moot and likewise the objections are moot.

In view of the amendments to the claims and arguments it is respectfully requested that the Examiner reconsider and withdraw the rejections and allow the claims as amended.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,

  
Bonnie L. Deppenbrock  
Attorney for Applicant  
Registration No. 28,209

Date: 11 February 2009  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Phone: 919-483-1577  
Facsimile: 919-483-7988